Cancer Stem Cell News Volume 4.20 | May 27 2015


    Cancer Stem Cell News 4.20 May 27, 2015

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook   CSCN on Twitter

    Chitosan-Decorated Doxorubicin-Encapsulated Nanoparticle Targets and Eliminates Tumor Reinitiating Cancer Stem-Like Cells
    Scientists developed a doxorubicin-encapsulated polymeric nanoparticle surface-decorated with chitosan that can specifically target the CD44 receptors of tumor reinitiating cancer stem-like cells. [ACS Nano] Abstract
    FREE Wallchart: Glioblastoma Multiforme

    PUBLICATIONS (Ranked by impact factor of the journal)
    RGD-Modified Oncolytic Adenovirus Exhibited Potent Cytotoxic Effect on CAR-Negative Bladder Cancer-Initiating Cells
    Scientists constructed Arg-Gly-Asp (RGD)-modified oncolytic adenovirus, carrying EGFP or TNF-related apoptosis-inducing ligand (TRAIL) gene, and applied them to coxsackie and adenovirus receptor (CAR)-negative bladder cancer T24 cells and cancer-initiating T24 sphere cells. [Cell Death Dis] Full Article

    Screening of Aptamers Specific to Colorectal Cancer Cells and Stem Cells by Utilizing On-Chip Cell-SELEX
    Researchers designed and manufactured a novel microfluidic system capable of performing a fully automated cell-based, systematic evolution of ligands by exponential enrichment (SELEX) process. Eight colorectal-cancer stem cells/colorectal cancer-specific aptamers were successfully selected using the microfluidic chip. [Sci Rep] Full Article

    Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells
    Investigators showed that epidermal growth factor receptor variant III (EGFRvIII) induces the expression and secretion of pigment epithelium-derived factor via activation of signal transducer and activator of transcription 3, thereby promoting self-renewal and tumor progression of glioma stem cells. [PLoS Biol] Full Article

    The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
    Investigators studied the combination treatment effects of HDAC inhibitors (HDACi) and Delta24-RGD in patient-derived glioblastoma stem-like cells, and they determined the most effective HDACi. [PLoS One] Full Article

    Mitochondrially Targeted Vitamin E Succinate Efficiently Kills Breast Tumor-Initiating Cells in a Complex II-Dependent Manner
    The mammosphere model of breast tumor-initiating cells was established by culturing murine NeuTL and human MCF7 cells as spheres. This model was verified by stem cell marker expression, tumor initiation capacity and chemotherapeutic resistance. [BMC Cancer] Full Article

    Plasminogen Activator Inhibitor-1 Regulates Tumor Initiating Cell Properties in Head and Neck Cancers
    Tiplaxtinin (PAI-039) suppressed the self-renewal capability of head and neck cancers (HNCs)-tumor initiating cells (TICs) derived from HNC cell lines through the inhibition of Sox2 expression. PAI-039 decreased the activity of the core promoter and the enhancer of Sox2 gene in HNC-TICs. [Head Neck-J Sci Spec] Abstract

    Targeting the Neurokinin-1 Receptor Inhibits Growth of Human Colon Cancer Cells
    Following neurokinin-1 receptor (NK1R) blockage, researchers found significant growth inhibition of both colon cancer cell lines. Treatment of colon cancer cells grown under cancer stem cell conditions reduced sphere formation in both number and size after a single treatment period. [Int J Oncol] Abstract

    The Histone Methyltransferase EZH2 Promotes Mammary Stem and Luminal Progenitor Cell Expansion, Metastasis and Inhibits Estrogen Receptor-Positive Cellular Differentiation in a Model of Basal Breast Cancer
    Using in vivo transplantation of mammary cancer stem cells transduced with enhancer of zeste homolog 2 (EZH2) or JMJD3 shRNAs, researchers demonstrated that EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation. [Oncol Rep] Abstract

    Request your FREE copy of STEMCELL Technologies' new 2015 catalog!

    Targeting of Cancer Stem Cells by Inhibitors of DNA and Histone Methylation
    Differentiation by embryonic stem cells and cancer stem cells is suppressed by gene silencing through the polycomb repressive complex 2 (PRC2) and/or DNA methylation. PRC2 contains the EZH2 subunit, which catalyzes the trimethylation of histone 3 lysine 27, a gene silencing marker. The authors discuss several specific EZH2 inhibitors that have been synthesized with antineoplastic activity. [Expert Opin Investig Drugs] Abstract

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

    Boston Biomedical to Highlight Data Examining Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types
    Boston Biomedical will present clinical data on the investigational compounds BBI608 and BBI503 in multiple tumor types. The study protocol from the BRIGHTER study, the Phase III clinical trial currently underway to investigate cancer stem cell pathway inhibitors, will also be showcased. [Press release from Boston Biomedical discussing research to be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

    From our sponsor:
    Webinar: Brent Reynolds on the identification and characterization of neural stem cells.
    Watch now.

    Cancer Prevention and Research Institute of Texas Awards 41 New Grants
    The Cancer Prevention and Research Institute of Texas awarded 28 grants through its academic research program, 11 grants through its prevention program and two grants through its product development research program. [Cancer Prevention and Research Institute of Texas] Press Release

    American Association for Cancer Research and Bayer Partner to Fund Fellowships to Advance Cancer Research
    The American Association for Cancer Research (AACR) and Bayer HealthCare announced a new partnership that will expand the AACR’s Basic Cancer Research Fellowship Program for 2015. [American Association for Cancer Research] Press Release

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    NEW Cancer Diagnosis & Therapy Congress
    September 3-4, 2015
    London, United Kingdom

    Visit our events page to see a complete list of events in the cancer stem cell community.

    NEW Postdoctoral Fellowship – Cancer Biology (University of California, San Francisco)

    Postdoctoral Positions – Cancer, Stem Cell, and Developmental Biology (Columbia University Medical Center)

    PhD Student – Cancer Stem Cell Immunology (Cardiff University)

    PhD Position – Neurology & Cancer Stem Cells (Cardiff University)

    Postdoctoral Positions – Epigenetics, Stem Cells and Cancer (University of Copenhagen)

    Postdoctoral Positions – Cancer Stem Cell Biology (Weill Cornell College of Medicine)

    Postdoctoral Position – Cancer Research (INSERM)

    Postdoctoral Research Fellow – Cell Death of Normal Tissue Stem Cells & Cancer Stem Cells (Memorial Sloan Kettering Cancer Center)

    Postdoctoral Position – Cancer Biology (University of Pennsylvania)

    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us